

# Leni van Doorn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3589944/publications.pdf>

Version: 2024-02-01

18  
papers

528  
citations

840776

11  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

931  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. <i>Cancers</i> , 2021, 13, 3915.	3.7	2
2	The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients. <i>Pharmaceuticals</i> , 2021, 14, 47.	3.8	4
3	Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma. <i>Pharmaceuticals</i> , 2021, 14, 46.	3.8	8
4	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. <i>Pharmaceutics</i> , 2020, 12, 788.	4.5	9
5	Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands. <i>Annals of Surgical Oncology</i> , 2019, 26, 4599-4607.	1.5	19
6	Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients. <i>Cancers</i> , 2019, 11, 826.	3.7	9
7	Sunitinib-induced blood pressure rise does not involve aldosterone. <i>Journal of Hypertension</i> , 2018, 36, 2279-2280.	0.5	6
8	Capecitabine and the Risk of Fingerprint Loss. <i>JAMA Oncology</i> , 2017, 3, 122.	7.1	19
9	Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2922-2929.	3.6	15
10	Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5738-5746.	7.0	68
11	Polymorphisms in <i>SLCO1B1</i> and <i>UGT1A1</i> are associated with sorafenib-induced toxicity. <i>Pharmacogenomics</i> , 2016, 17, 1483-1490.	1.3	26
12	A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies. <i>Clinical Colorectal Cancer</i> , 2015, 14, 18-24.e1.	2.3	10
13	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. <i>Clinical Cancer Research</i> , 2015, 21, 2297-2304.	7.0	69
14	A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2687-2694.	7.0	66
15	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 4425-4432.	7.0	34
16	Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma. <i>Thyroid</i> , 2011, 21, 197-202.	4.5	33
17	Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 7156-7163.	7.0	89
18	Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor $\beta$ , and c-Kit, in Patients With Advanced or Metastatic Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 4169-4176.	1.6	42